Table 2.
Efficacy of first-line treatment strategies in patients with BRAF mutation.
| Treatment strategies in first-line | V600E | Non-V600E | ||
|---|---|---|---|---|
| DCR | PFS months, (95%CI) | DCR | PFS months, (95%CI) | |
| Pemetrexed-contained chemotherapy | 11/14, 78.6% | 5.4 (1.7, 9.1) | 5/7, 71.4% | 5.4 (1.3, 9.5) |
| Paclitaxel-contained chemotherapy | 2/5, 40.0% | 1.5 (1.1, 1.9) | – | – |
| Vemurafenib | 9/9, 100.0% | 9.8 (0.7, 18.9) | – | – |
| Dabrafenib | 1/1, 100.0% | – | – | – |
| Dabrafenib + Trametinib | 5/5, 100.0% | NR | – | – |
DCR, disease control rate; PFS, progression-free survival; NR, not reached.